Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
Application for MHRA Regulatory Certification of Facility In Preparation
News provided by
Share this article
Share this article
BETHESDA, Md., March 16, 2021 /PRNewswire/ Northwest Biotherapeutics (OTCQB: NWBO) ( NW Bio ), a biotechnology company developing DCVax
® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company s Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK Medicines and Health Products Regulatory Authority ( MHRA ).
proteins that targeted specific proteins. this does a smorgasbord. can you get into the trial if you re a patient in how does that work? a lot of people are asking me that over the last few days and sending them over to the manufacturer, northwest biotherapeutics to see perhaps on the website or on the national institutes of health, national cancer institute, you can get more information. absolutely. is this an allogenic vaccine? it s an allogenic. you use your own cells, your own tumor. basically the patient has the cancer, then they remove the tumor from his or her s own tumor cell, then they create a vaccine. it s not a vaccine coming from other donors. by the way, i should add that only takes eight days. that process takes eight days. costs $100,000 for 3 years and have enough to treat you for three or four years. i think that s five vaccine trials are going on